Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (CLLS) news covers the activities of a clinical-stage biotechnology company focused on gene-edited cell and gene therapies. The company regularly issues updates on its allogeneic CAR-T pipeline, gene-editing technology advances, strategic collaborations, and financial position, providing a detailed view of how its programs evolve over time.
Investors and observers following Cellectis news can read about clinical data from key trials such as BALLI-01 for lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia and NATHALI-01 for eti-cel (UCART20x22) in relapsed/refractory non-Hodgkin lymphoma. Press releases describe response rates, safety findings, and trial design features, as well as plans for pivotal Phase 2 development and data presentations at major scientific meetings.
Cellectis also publishes research and technology updates, including work on circular single-stranded DNA (CssDNA) as a non-viral donor template for gene insertion in hematopoietic stem and progenitor cells and studies of TALE base editors in primary T cells. These announcements highlight how the company applies its gene-editing platform beyond CAR-T therapies.
Additional news items address collaborations with partners such as AstraZeneca, Servier, Allogene, and Iovance, along with arbitration outcomes, financial results, cash runway disclosures, and monthly information on share capital and voting rights. By reviewing this news feed, readers can track both scientific progress and corporate developments that shape the outlook for Cellectis and its CLLS listing.
Cellectis (NASDAQ: CLLS) presented its 'Smart CAR T' strategy at AACR-IO 2025, showcasing an innovative approach to enhance CAR T cell efficacy against solid tumors. The presentation focused on a technique using interleukin 2 (IL-2) to improve treatment outcomes.
The company's research demonstrates that their TALEN® gene editing technology enables CAR T cells to express a CAR-inducible IL-2 variant (IL-2v) immunocytokine, which is activated by tumor-specific signals within the solid tumor microenvironment (TME). This engineered IL-2v boosts anti-tumor activity both in vitro and in vivo, while minimizing systemic toxicity by anchoring to the FAP protein present in the TME.
The development aims to improve CAR T-cell expansion and persistence without the toxicity risks typically associated with high-dose IL-2 administration, potentially representing a safer and more effective treatment approach for solid tumors.
Cellectis has released its monthly share capital and voting rights update as of January 31, 2025, in accordance with Article 223-16 of the French financial markets authority's General Regulation. The company reported a total of 100,093,873 shares in capital and 88,660,571 voting rights. This information was disclosed for the Euronext Growth market, where Cellectis trades under the ISIN code FR0010425595.
Cellectis has released its monthly share capital and voting rights report as of December 31, 2024. The company reported a total of 100,093,873 shares in the capital and 88,660,539 voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, as the company is listed on Euronext Growth under ISIN code FR0010425595.
Cellectis (NASDAQ: CLLS) has drawn down the final €5 million tranche (Tranche C) from its €40 million credit facility agreement with the European Investment Bank (EIB). The disbursement is expected by December 18, 2024, completing the full €40 million facility established on December 28, 2022.
The funds will support the development of Cellectis' allogeneic CAR T-cell product candidates: UCART22 and UCART20x22. As part of the agreement, Cellectis issued 611,426 warrants to the EIB, each convertible into one ordinary share at €1.70 per share, representing approximately 0.6% of the company's outstanding shares. Tranche C has a six-year maturity with a 6% annual interest rate, capitalized annually and payable at maturity.
Cellectis has released its monthly share capital and voting rights information as of November 30, 2024. The company reported a total of 100,093,873 shares in the capital and 88,576,206 voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, with the company's shares listed on Euronext Growth under ISIN code FR0010425595.
Cellectis has reported its monthly share capital and voting rights information as of October 31, 2024. The company disclosed a total of 100,093,873 shares in the capital and 88,569,210 voting rights. This disclosure is made in compliance with Article 223-16 of the General Regulation of the French financial markets authority for its listing on Euronext Growth under ISIN code FR0010425595.
Cellectis announced pre-clinical data presentation at SITC's 39th Annual Meeting, showcasing strategies to enhance CAR T-cell efficacy against solid tumors. The research focuses on overcoming challenges in the tumor microenvironment (TME) using TALEN®-mediated gene editing to generate allogeneic CAR T-cells. The company developed two key approaches: a FAP-dependent expression system to limit cytotoxic activity to tumor areas, and integration of IL-12 into PD-1 regulatory elements while inactivating TGFBR2. These strategies showed enhanced T-cell proliferation and infiltration while reducing tumor burden and limiting side effects, potentially offering new therapeutic options for solid tumor patients.
Cellectis (CLLS) reported Q3 2024 business updates and financial results, highlighting ongoing enrollment in UCART22 and UCART20x22 clinical trials, with Phase 1 dataset expected in 2025. The company's cash position stands at $264 million as of September 30, 2024, projecting runway into 2027. Research and development activities have commenced on three programs under the AstraZeneca partnership. The company reported revenues of $34.1 million for the nine months ended September 30, 2024, compared to $7.2 million in the same period of 2023. Net loss was $42.7 million, an improvement from the $59.3 million loss in the previous year.
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapies, has announced it will release its third quarter 2024 financial results on November 4, 2024 after US market close. The company will host an investor conference call and webcast on November 5, 2024 at 8:00 AM ET / 2:00 PM CET to discuss the quarterly results and provide a business update.
Cellectis, a clinical-stage biotechnology company, will present pre-clinical data on TALE base editors (TALEB) and non-viral gene insertion at the European Society of Cell and Gene Therapy 31st annual congress in Roma, Italy, from October 22-25, 2024. Two posters will be showcased:
1. 'Controlling C-to-T editing with TALE base editors' by Alexandre Juillerat, Ph.D., on October 24. This study enhances understanding of TALEB and allows for the design of efficient and specific tools potentially compatible with therapeutic applications.
2. 'Circular Single-Stranded DNA Enables Efficient TALEN-Mediated Gene Insertion in Long Term HSC' by Julien Valton, Ph.D., also on October 24. This research demonstrates that circularizing ssDNA increases gene insertion rates in long-term HSCs and may enhance their engraftment capacity in preclinical murine models, advancing non-viral gene therapy.
FAQ
What is the current stock price of Cellectis (CLLS)?
What is the market cap of Cellectis (CLLS)?
